Poor
Not Aligned
Patient Risk:
Moderate
Summary
Major portion of claim verification lacks verifiable alignment to FDA label sections provided in the prompt; multiple safety-critical areas (contraindications, pregnancy, pediatric specifics beyond dosage, and interaction language) are not demonstrably assessed with label citations. Several patient-instruction claims (“seek urgent care…”) are marked unsupported/absent without showing label-prompt-backed justification.
Category Scores
Accurate Statements
Etodolac use for relief of signs and symptoms of juvenile rheumatoid arthritis, rheumatoid arthritis, and osteoarthritis is supported by the Indications and Usage section.
Indications and Usage
NSAID-related GI ulceration/bleeding/perforation risk is supported by Warnings and Boxed Warning.
Warnings (Gastrointestinal Effects - Risk of Ulceration, Bleeding, and Perforation); Boxed Warning (Gastrointestinal Risk)
NSAID-related renal effects risk is supported by Warnings (Renal Effects) and Adverse Reactions (e.g., abnormal renal function, renal failure/insufficiency).
Warnings (Renal Effects); Adverse Reactions
NSAID-related cardiovascular thrombotic events risk is supported by the Boxed Warning and Warnings (Cardiovascular Thrombotic Events).
Boxed Warning (Cardiovascular Thrombotic Events); Warnings (Cardiovascular Effects - Cardiovascular Thrombotic Events)
Patients with prior ulcer disease/GI bleeding are described as high risk with NSAIDs and should be treated with extreme caution; alternate therapies may be considered.
Warnings (Gastrointestinal Effects - Risk of Ulceration, Bleeding, and Perforation)
Advanced renal disease: treatment is not recommended; if initiated, close monitoring is advised.
Warnings (Advanced Renal Disease)
Unsupported Statements
“Seek urgent care for signs of gastrointestinal bleeding such as black/tarry stools or vomiting blood.”
The evaluation cannot demonstrate this patient-instruction language or those specific examples are present in the provided label text.
“Seek urgent care for signs of allergic reactions such as facial swelling or trouble breathing.”
The evaluation cannot demonstrate this patient-instruction language or the specific example 'trouble breathing' is present in the provided label text.
“Etodolac 500 mg is a prescription-strength nonsteroidal anti-inflammatory drug (NSAID).”
No explicit standalone label wording for 'prescription-strength' in the provided excerpts; the evaluation relies on contextual NSAID identification rather than verifiable excerpt wording for this formulation.
Several 'supported/partially_supported' determinations were not accompanied by precise label section citations as required by the prompt (e.g., Dosage/Indications alignment without explicit section-number mapping).
The analysis references label sections generally but does not provide precise, citable label references per claim.
Contradictions
Important Omissions
Contraindications were not adequately evaluated with explicit label alignment for the specific etodolac formulation/context (hypersensitivity; NSAID-exacerbated asthma/urticaria; CABG surgery).
Importance:
High
Use in specific populations (notably pregnancy/late pregnancy risks and any pediatric-specific contraindications/warnings beyond dosing) was not assessed or cited.
Importance:
High
Drug interactions: only general caution was addressed; the provided excerpts include specific mechanistic/clinical cautions (e.g., BP effects with diuretics; ACE inhibitors/ARBs; anticoagulants/corticosteroids for GI bleed risk) that were not fully tied to claims with verifiable label citation per claim.
Importance:
Moderate
Safety-critical boxed warning/precautions coverage for any claims of 'do not increase dose/frequency without prescriber' was not verified with direct label language (dose optimization is present, but the exact behavioral prohibition was not shown).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Key safety domains (contraindications and specific-population warnings, including pregnancy) were not demonstrably assessed; two explicit patient-instruction claims about urgent care were not shown to be present in the provided label text.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Insufficient label-citation verification for multiple claims, especially contraindications and specific-population safety language; patient-instruction claims are not shown in the provided label excerpts.
Suggested Improvement
Re-evaluate each claim using exact FDA label section text/anchors from the provided label excerpts (Contraindications; Boxed Warning; Warnings and Precautions subsections including GI/CV/renal/hypersensitivity; Dosage and Administration with product/formulation-specific timing; and Use in Specific Populations such as pregnancy and pediatric warnings). Provide explicit label-supported excerpts for patient instructions and for any 'avoid/use with supervision' phrasing.